Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Winlevi | clascoterone | Acne vulgaris | Pending | |||
| Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xalkori | Crizotinib | Advanced Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Xalkori | Crizotinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xalkori | Crizotinib | First Line ALK Positive Advanced NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | Complete | |||
| Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
| Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
| Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Venous thromboembolism, prevention | N/A | Complete | ||
| Xarelto | Rivaroxaban | Atrial fibrillation, stroke prevention | List with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | List with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban (granules for oral suspension) | Venous Thromboembolic Events | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Xcopri | cenobamate | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeljanz | tofacitinib | Cancelled | ||||
| Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Xeomin | incobotulinumtoxinA | Chronic sialorrhea associated with neurological disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Blepharospasm | List in a similar manner | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Cervical Dystonia | List in a similar manner | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Spasticity, Post-stroke | Do not list | Complete | ||
| Xermelo | telotristat | carcinoid syndrome | Do not reimburse | Complete | ||
| Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from breast cancer | List with clinical criteria and/or conditions | Complete | ||
| XGEVA | Denosumab | Prevention of skeletal-related events due to bone metastases from solid tumours | List with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024